ClinicalTrials.gg
CompletedNCT01859039SNIFFLEUpdated Aug 10, 2020

Safety of Nasal Influenza Immunisation in Egg Allergic Children

An observational study in Egg Hypersensitivity, sponsored by University Hospital Southampton NHS Foundation Trust. Completed at 12 sites in United Kingdom. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by University Hospital Southampton NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
282
Ages
2 Years to 17 Years
Sex
All
01

Study summary

Egg allergy is common in early childhood, affecting at least one in 50 preschool children. Influenza ("'flu") vaccines contain egg protein, as the vaccine is cultured in hen's eggs. There is robust data to support the safety of influenza vaccines (containing low or negligible amounts of egg protein) in patients with egg allergy.

A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. This new vaccine has been available in the United States for several years and is highly effective and against influenza infection, with an excellent safety profile in children without egg allergy. However, LAIV is also grown in hen's eggs and contains egg protein, and there are NO existing data on the safety of LAIV in egg-allergic children.

The objective of this multicentre study is to assess the safety of intranasal LAIV in egg-allergic children, in order to demonstrate that these children can safely be given the new LAIV within a primary care health environment.

02

Conditions studied

  • Egg Hypersensitivity

Keywords

  • Egg allergy
  • Anaphylaxis
  • Children
  • Influenza vaccine
03

In context

Egg Hypersensitivity

38 studies on the registry are indexed under Egg Hypersensitivity; 9 are open to participants now.

Browse Egg Hypersensitivity studies →

Lead sponsor

University Hospital Southampton NHS Foundation Trust is the lead sponsor of 150 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and young people with egg allergy between 2-17 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2 - 17 years old
  • Physician-diagnosis of egg allergy

Exclusion criteria

Exclusion Criteria:

  • as acutely unwell or current unstable asthma
  • Use of asthma reliever medication in last 72 hours
  • Recent administration of a medication containing antihistamine within the last 4 days
  • Current oral for asthma exacerbation or course completed within last 2 weeks
  • Contraindications to ingredient in LAIV (notwithstanding allergy to egg protein)
  • Previous allergic reaction to an influenza vaccine
  • Children and adolescents who are clinically immunodeficient due to conditions or therapy such as: acute and chronic leukaemias; lymphoma; symptomatic infection; cellular immune deficiencies; and high-dose corticosteroids.
  • Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
282 participants (actual)
Patient registry
No

Groups and cohorts

  • Egg allergic children

    Administration of Live attenuated influenza vaccine

    Biological: Administration of Live attenuated influenza vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of allergic reaction to nasal influenza vaccination using a Live Attenuated Influenza Vaccine (LAIV) in egg-allergic children

    Time frame: Within 2 hours of vaccine administration

Secondary outcomes

  1. Incidence of delayed symptoms up to 72 hours after nasal influenza vaccination with LAIV in egg-allergic children

    Time frame: 72 hours after vaccine administration

Other outcomes

  1. Incidence of immediate allergic reaction to LAIV in the subgroups described below.

    1. By age group 2-5, 5-11, 12-17 years 2. children with a previous history of anaphylaxis to egg protein, 3. children who have reacted previously to airborne traces of egg, 4. children who have egg allergy but are tolerant of baked egg, 5. Presence of physician-diagnosed asthma / recurrent wheeze 6. Presence of active allergic rhinitis to common environmental indoor allergens

    Time frame: Within 2 hours of vaccine administration

07

Study locations

12 sites
  • Sandwell General Hospital
    Birmingham, United Kingdom
  • Bristol Royal Hospital for Children
    Bristol, United Kingdom
  • Royal Hospital for Sick Children
    Edinburgh, United Kingdom
  • Leicester Royal Infirmary
    Leicester, United Kingdom
  • Alder Hey Children's Hospital
    Liverpool, United Kingdom
  • Evelina Children's Hospital
    London, United Kingdom
  • Imperial College Healthcare NHS Trust (St. Mary's Hospital)
    London, United Kingdom
  • London St George's Hospital
    London, United Kingdom
  • Manchester Royal Children's
    Manchester, United Kingdom
  • Newcastle Freeman Hospital
    Newcastle, United Kingdom
  • Oxford
    Oxford, United Kingdom
  • University Hospitals Southampton NHS Foundation Trust
    Southampton, United Kingdom
08

References and documents

Publications

  • Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015 Aug;136(2):376-81. doi: 10.1016/j.jaci.2014.12.1925. Epub 2015 Feb 13. PubMed 25684279 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01859039
Collaborators
Imperial College London, Public Health England
Responsible party
Paul Turner (MRC Clinician Scientist in Paediatric Allergy & Immunology, Imperial College London) — Principal investigator
First posted
May 21, 2013
Start date
Sep 2013
Primary completion
Feb 2014
Completion
Feb 2014
Last update
Aug 10, 2020

Study contacts

Paul J Turner, FRACP PhD
principal investigator · Imperial College London
Mich Erlewyn-Lajeunesse, DM FRCPCH
principal investigator · University Hospitals Southampton NHS Foundation Trust

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion